summary
Introduced
02/24/2025
02/24/2025
In Committee
03/18/2025
03/18/2025
Crossed Over
03/18/2025
03/18/2025
Passed
03/21/2025
03/21/2025
Dead
Signed/Enacted/Adopted
03/28/2025
03/28/2025
Introduced Session
2025-2026 Regular Session
Bill Summary
Current law requires the Controlled Substances Board to establish a prescription drug monitoring program (PDMP) that requires pharmacies and health care practitioners to generate records documenting the dispensing of monitored prescription drugs. Records from the PDMP may be disclosed to persons specified under current law or by the board by rule. This bill makes changes to certain requirements under the PDMP: 1. Subject to exceptions, current law requires that a patient[s records under the program be reviewed before a practitioner issues a prescription order for the patient. However, current law provides that this requirement does not apply after April 1, 2025. The bill extends the application of this requirement by five years, to April 1, 2030. 2. Current law requires the board to conduct a quarterly review of the PDMP to evaluate the actual outcomes of the PDMP compared with projected outcomes. However, current law provides that this requirement does not apply after October 30, 2025. The bill extends the application of this requirement by five years, to October 30, 2030. For further information see the state fiscal estimate, which will be printed as an appendix to this bill. LRB-2165/1 MED:skw 2025 - 2026 Legislature SENATE BILL 68
AI Summary
This bill extends two key provisions related to the Prescription Drug Monitoring Program (PDMP), a system that tracks prescription medications to help prevent drug misuse and potential overdoses. First, the bill continues the requirement that healthcare practitioners review a patient's prescription records in the PDMP before issuing a new prescription order, extending this mandate from April 1, 2025, to April 1, 2030. Second, the bill prolongs the Controlled Substances Board's obligation to conduct quarterly reviews of the PDMP, comparing actual program outcomes to projected outcomes, by extending the review requirement from October 30, 2025, to October 30, 2030. These extensions will help ensure continued oversight and monitoring of prescription drug dispensing, potentially allowing healthcare providers and regulatory bodies to maintain valuable insights into prescription drug usage patterns and effectiveness of the monitoring program.
Committee Categories
Health and Social Services
Sponsors (2)
Last Action
Published 3-29-2025 (on 03/28/2025)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
| Document Type | Source Location |
|---|---|
| State Bill Page | https://docs.legis.wisconsin.gov/2025/proposals/reg/sen/bill/sb68 |
| Analysis - 2025 Wisconsin Act 5: LC Act Memo | https://docs.legis.wisconsin.gov/document/lcactmemos/2025/REG/Act%205.pdf |
| BillText | https://docs.legis.wisconsin.gov/document/acts/2025/5.pdf |
| BillText | https://docs.legis.wisconsin.gov/document/enrolledbills/2025/REG/SB68.pdf |
| SB68 ROCP for Committee on Mental Health, Substance Abuse Prevention, Children and Families On 3/7/2025 | https://docs.legis.wisconsin.gov/2025/related/records/senate/mental_health_substance_abuse_prevention_children_and_families/1907824.pdf |
| Fiscal Note - SB68: Fiscal Estimate From DSPS | https://docs.legis.wisconsin.gov/2025/related/fe/sb68/sb68_dsps.pdf |
| BillText | https://docs.legis.wisconsin.gov/document/proposaltext/2025/REG/SB68.pdf |
Loading...